Screener
Monte Rosa Therapeutics, Inc. GLUE Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
FAQ
- What is Monte Rosa Therapeutics, Inc.'s total liabilities?
- Monte Rosa Therapeutics, Inc. (GLUE) reported total liabilities of $203.88M in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s total liabilities changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s total liabilities increased by 122.8% year-over-year, from $91.51M to $203.88M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s total liabilities has grown at a 48.0% compound annual growth rate (CAGR), from $30.34M to $215.6M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Monte Rosa Therapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude